127562-53-2

Basic information

• Product Name: 4-(1,4-dioxaspiro[4.5]decan-8-yl)morpholine
• Synonyms: 4-(1,4-dioxaspiro[4.5]decan-8-yl)morpholine
• CAS NO: 127562-53-2
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227.30004
• Mol File: 127562-53-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(1,4-dioxaspiro[4.5]decan-8-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,4-dioxaspiro[4.5]decan-8-yl)morpholine(127562-53-2)
• EPA Substance Registry System: 4-(1,4-dioxaspiro[4.5]decan-8-yl)morpholine(127562-53-2)

Safety Data

• Hazardous Substances Data: 127562-53-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(1,4-dioxaspiro[4.5]decan-8-yl)morpholine is used as an intermediate in the synthesis of T3026350, a reactant used in the preparation of azaindole derivatives. These azaindole derivatives are c-Jun N-terminal kinase (JNK) inhibitors, which play a crucial role in the regulation of cell apoptosis, inflammation, and immune responses. As a result, they have potential applications in the development of therapeutic agents for various diseases, including neurodegenerative disorders, inflammatory conditions, and cancer.

Upstream product

• 110-91-8 morpholine 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 139025-93-7 4-(morpholin-4-yl)cyclohexan-1-one 
• 139025-94-8 C₁₄H₂₄N₂O₂ 
• 155778-83-9 4-(1,4-dioxaspiro<4,5>dec-8-yl)-1-methylpiperazine 
• 1046793-55-8 4-morpholinocyclohex-1-en-1-yl trifluoromethanesulfonate 
• 1046793-56-9 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)morpholine 

Relevant articles and documents

Cobalt-Catalyzed Desymmetric Isomerization of Exocyclic Olefins

Chiral cyclic olefins, 1-methylcyclohexenes, are versatile building blocks for the synthesis of pharmaceuticals and natural products. Despite the prevalence of these structural motifs, the development of efficient synthetic methods remains an unmet challenge. Herein we report a novel desymmetric isomerization of exocyclic olefins using a series of newly designed chiral cobalt catalysts, which enables a straightforward construction of chiral 1-methylcyclohexenes with diversified functionalities. The synthetic utility of this methodology is highlighted by a concise and enantioselective synthesis of a natural product, β-bisabolene. The versatility of the reaction products is further demonstrated by multifarious derivatizations.

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE

The invention relates to diazaindole derivatives represented by the general formula (I): where A, E, G, R1, R2, R3 and R4 are defined herein, or pharmaceutically acceptable salts thereof, their use in the inhibition of c-Jun N-terminal kinase (JNK) activity, their use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases, autoimmune diseases and/or organ failure. The invention also provides processes for the manufacture of said diazaindole derivatives and compositions containing them.

THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE

The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and

7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE

The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, es

Synthesis of diastereomeric 3,6-diaminobicyclo[3.1.0]hexane derivatives: A stereocomplementary approach

Diastereomeric (1α,3β,5α,6β)- and (1α,3α,5α,6β)-diaminobicyclo [3.1.0]hexane-6-carbonitriles 12 and 16 were synthesized with high stereoselectivity from 1,4-cyclohexanedione monoacetal 6 via chloroenamines 17 and 18, respectively. The sequence of reaction